Dr Osterwalder is a board certified hematologist and oncologist with a background of 15 years of academic and clinical practice in internal medicine, hematology and oncology (Swiss Board Certifications). This was followed by 24 years in global drug development and strategic portfolio management in the fields of oncology and immune-oncology drug development at F. Hoffmann-La Roche (VP Clinical development (anemia)) and Merck Serono (Senior VP & Senior Strategic Adviser (Oncology)). Bruno was actively involved in the cilengitide drug development process during this tenure. Since 2015, Bruno has acted as a consultant and board member to pharmaceutical companies in the area of global strategic drug development with a focus in oncology, hematology and immune-oncology. Specific interests include the transition from preclinical to clinical development, and the combined development of companion diagnostics and therapeutic drugs in the context of targeted therapies and stratified medicine. Dr Osterwalder is a member of professional societies such as ASCO, AACR, ASH, ECCO and ESMO
